Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

CFTR Correctors and Antioxidants Partially Normalize Lipid Imbalance but not Abnormal Basal Inflammatory Cytokine Profile in CF Bronchial Epithelial Cells

M. Veltman, JB. De Sanctis, M. Stolarczyk, N. Klymiuk, A. Bähr, RW. Brouwer, E. Oole, J. Shah, T. Ozdian, J. Liao, C. Martini, D. Radzioch, JW. Hanrahan, BJ. Scholte

. 2021 ; 12 (-) : 619442. [pub] 20210204

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21010529

A deficiency in cystic fibrosis transmembrane conductance regulator (CFTR) function in CF leads to chronic lung disease. CF is associated with abnormalities in fatty acids, ceramides, and cholesterol, their relationship with CF lung pathology is not completely understood. Therefore, we examined the impact of CFTR deficiency on lipid metabolism and pro-inflammatory signaling in airway epithelium using mass spectrometric, protein array. We observed a striking imbalance in fatty acid and ceramide metabolism, associated with chronic oxidative stress under basal conditions in CF mouse lung and well-differentiated bronchial epithelial cell cultures of CFTR knock out pig and CF patients. Cell-autonomous features of all three CF models included high ratios of ω-6- to ω-3-polyunsaturated fatty acids and of long- to very long-chain ceramide species (LCC/VLCC), reduced levels of total ceramides and ceramide precursors. In addition to the retinoic acid analog fenretinide, the anti-oxidants glutathione (GSH) and deferoxamine partially corrected the lipid profile indicating that oxidative stress may promote the lipid abnormalities. CFTR-targeted modulators reduced the lipid imbalance and oxidative stress, confirming the CFTR dependence of lipid ratios. However, despite functional correction of CF cells up to 60% of non-CF in Ussing chamber experiments, a 72-h triple compound treatment (elexacaftor/tezacaftor/ivacaftor surrogate) did not completely normalize lipid imbalance or oxidative stress. Protein array analysis revealed differential expression and shedding of cytokines and growth factors from CF epithelial cells compared to non-CF cells, consistent with sterile inflammation and tissue remodeling under basal conditions, including enhanced secretion of the neutrophil activator CXCL5, and the T-cell activator CCL17. However, treatment with antioxidants or CFTR modulators that mimic the approved combination therapies, ivacaftor/lumacaftor and ivacaftor/tezacaftor/elexacaftor, did not effectively suppress the inflammatory phenotype. We propose that CFTR deficiency causes oxidative stress in CF airway epithelium, affecting multiple bioactive lipid metabolic pathways, which likely play a role in CF lung disease progression. A combination of anti-oxidant, anti-inflammatory and CFTR targeted therapeutics may be required for full correction of the CF phenotype.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21010529
003      
CZ-PrNML
005      
20210715080815.0
007      
ta
008      
210413s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphys.2021.619442 $2 doi
035    __
$a (PubMed)33613309
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Veltman, Mieke $u Cell Biology Department, Erasmus Medical Center, Rotterdam, Netherlands ; Pediatric Pulmonology, Sophia Children's Hospital, Erasmus Medical Center, Rotterdam, Netherlands
245    10
$a CFTR Correctors and Antioxidants Partially Normalize Lipid Imbalance but not Abnormal Basal Inflammatory Cytokine Profile in CF Bronchial Epithelial Cells / $c M. Veltman, JB. De Sanctis, M. Stolarczyk, N. Klymiuk, A. Bähr, RW. Brouwer, E. Oole, J. Shah, T. Ozdian, J. Liao, C. Martini, D. Radzioch, JW. Hanrahan, BJ. Scholte
520    9_
$a A deficiency in cystic fibrosis transmembrane conductance regulator (CFTR) function in CF leads to chronic lung disease. CF is associated with abnormalities in fatty acids, ceramides, and cholesterol, their relationship with CF lung pathology is not completely understood. Therefore, we examined the impact of CFTR deficiency on lipid metabolism and pro-inflammatory signaling in airway epithelium using mass spectrometric, protein array. We observed a striking imbalance in fatty acid and ceramide metabolism, associated with chronic oxidative stress under basal conditions in CF mouse lung and well-differentiated bronchial epithelial cell cultures of CFTR knock out pig and CF patients. Cell-autonomous features of all three CF models included high ratios of ω-6- to ω-3-polyunsaturated fatty acids and of long- to very long-chain ceramide species (LCC/VLCC), reduced levels of total ceramides and ceramide precursors. In addition to the retinoic acid analog fenretinide, the anti-oxidants glutathione (GSH) and deferoxamine partially corrected the lipid profile indicating that oxidative stress may promote the lipid abnormalities. CFTR-targeted modulators reduced the lipid imbalance and oxidative stress, confirming the CFTR dependence of lipid ratios. However, despite functional correction of CF cells up to 60% of non-CF in Ussing chamber experiments, a 72-h triple compound treatment (elexacaftor/tezacaftor/ivacaftor surrogate) did not completely normalize lipid imbalance or oxidative stress. Protein array analysis revealed differential expression and shedding of cytokines and growth factors from CF epithelial cells compared to non-CF cells, consistent with sterile inflammation and tissue remodeling under basal conditions, including enhanced secretion of the neutrophil activator CXCL5, and the T-cell activator CCL17. However, treatment with antioxidants or CFTR modulators that mimic the approved combination therapies, ivacaftor/lumacaftor and ivacaftor/tezacaftor/elexacaftor, did not effectively suppress the inflammatory phenotype. We propose that CFTR deficiency causes oxidative stress in CF airway epithelium, affecting multiple bioactive lipid metabolic pathways, which likely play a role in CF lung disease progression. A combination of anti-oxidant, anti-inflammatory and CFTR targeted therapeutics may be required for full correction of the CF phenotype.
655    _2
$a časopisecké články $7 D016428
700    1_
$a De Sanctis, Juan B $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University, Olomouc, Czechia
700    1_
$a Stolarczyk, Marta $u Cell Biology Department, Erasmus Medical Center, Rotterdam, Netherlands
700    1_
$a Klymiuk, Nikolai $u Large Animal Models for Cardiovascular Research, TU Munich, Munich, Germany ; Center for Innovative Medical Models, LMU Munich, Munich, Germany
700    1_
$a Bähr, Andrea $u Large Animal Models for Cardiovascular Research, TU Munich, Munich, Germany ; Center for Innovative Medical Models, LMU Munich, Munich, Germany
700    1_
$a Brouwer, Rutger W $u Cell Biology Department, Erasmus Medical Center, Rotterdam, Netherlands ; Center for Biomics, Erasmus Medical Center, Rotterdam, Netherlands
700    1_
$a Oole, Edwin $u Cell Biology Department, Erasmus Medical Center, Rotterdam, Netherlands ; Center for Biomics, Erasmus Medical Center, Rotterdam, Netherlands
700    1_
$a Shah, Juhi $u Department of Medicine, The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
700    1_
$a Ozdian, Tomas $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University, Olomouc, Czechia
700    1_
$a Liao, Jie $u Department of Physiology, CF Translational Research Centre, McGill University, Montreal, QC, Canada
700    1_
$a Martini, Carolina $u Department of Physiology, CF Translational Research Centre, McGill University, Montreal, QC, Canada
700    1_
$a Radzioch, Danuta $u Department of Medicine, The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
700    1_
$a Hanrahan, John W $u Department of Medicine, The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada ; Department of Physiology, CF Translational Research Centre, McGill University, Montreal, QC, Canada
700    1_
$a Scholte, Bob J $u Cell Biology Department, Erasmus Medical Center, Rotterdam, Netherlands ; Pediatric Pulmonology, Sophia Children's Hospital, Erasmus Medical Center, Rotterdam, Netherlands
773    0_
$w MED00174601 $t Frontiers in physiology $x 1664-042X $g Roč. 12, č. - (2021), s. 619442
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33613309 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210413 $b ABA008
991    __
$a 20210715080814 $b ABA008
999    __
$a ind $b bmc $g 1649843 $s 1130905
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 12 $c - $d 619442 $e 20210204 $i 1664-042X $m Frontiers in physiology $n Front. physiol. $x MED00174601
LZP    __
$a Pubmed-20210413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...